Silence Therapeutics (SLN) Total Current Liabilities (2018 - 2026)

Silence Therapeutics (SLN) has 9 years of Total Current Liabilities data on file, last reported at $10.5 million in Q1 2026.

• For the quarter ending Q1 2026, Total Current Liabilities fell 45.7% year-over-year to $10.5 million; the trailing twelve-month figure through Mar 2026 stood at $10.5 million (down 45.7% YoY), and the FY2025 full-year result was $13.6 million, down 19.08% from the prior year.
• Total Current Liabilities declined to $10.5 million in Q1 2026, from $13.6 million in the prior quarter.
• In the past five years, Total Current Liabilities ranged from a high of $25.7 million in Q4 2022 to a low of $10.5 million in Q1 2026.
• A 5-year average of $17.5 million and a median of $17.1 million in 2024 frame the typical range for Total Current Liabilities.
• Across the five-year window, Total Current Liabilities gained 25.89% in 2022 and sank 45.7% in 2026, its largest moves.
• Tracing SLN's Total Current Liabilities over 5 years: stood at $25.7 million in 2022, then fell by 14.31% to $22.1 million in 2023, then dropped by 23.72% to $16.8 million in 2024, then fell by 19.08% to $13.6 million in 2025, then slipped by 23.16% to $10.5 million in 2026.
• Business Quant data shows SLN's Total Current Liabilities at $10.5 million in Q1 2026, $13.6 million in Q4 2025, and $17.4 million in Q3 2025.